Health TrialsbyHealthPanel

IC-MPGN

3

Review clinical trials related to IC-MPGN. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Chinese Adults With Kidney Disease

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ADARx Pharmaceuticals, Inc.Updated: Sep 3, 2026Locations: 9
Eligibility criteria

Mean eGFR greater than or equal to 30 mL/min/1.73m2 [+4]

Previous kidney transplant or major solid organ transplant [+6]

Read more
Status: Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Participants needed: 45
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ADARx Pharmaceuticals, Inc.Updated: Sep 3, 2026Locations: 38
Eligibility criteria

Mean eGFR greater than or equal to 30 mL/min/1.73m2 [+4]

Hereditary or acquired complement deficiency [+7]

Read more
Status: Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

Participants needed: 106
Trial details
Phase: Phase 3Age: 12-60Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 13, 2026Locations: 131
Eligibility criteria

Male and female patients including adults (aged at least 18 years to ≤ 60 years)... [+6]

Participants who have undergone cell or solid organ transplantation, including k... [+17]

Read more